Announcement: Chime Biologics appoints Dr. John (Xianfang) Zeng as new CEO
Chime Biologics announced that Dr. John (Xianfang) Zeng, a technical leader and commercial operation expert in biopharmaceutical industry, had joined Chime Biologics on January 1, 2021 as new CEO to oversee the business and operational management of the company.
Dr. John (Xianfang) Zeng has over 20 years of international leadership experience in biologics, vaccines, cell therapy product development and cGMP commercial production, and has successfully led several biologics and vaccine programs from the research and development stage to commercialization. Before joining Chime Biologics, Dr. Zeng served as the Executive Vice President of Shanghai Zerun Biotech and General Manager of Yuxi Zerun Biotech where he was responsible for preclinical and clinical product development, cGMP large scale commercialization, and regulatory registration of new vaccines and biological products. He has also held senior management positions in internationally renowned companies such as Dendreon, Lonza and GSK. Dr. John (Xianfang) Zeng holds a Ph.D. degree in Biochemical Engineering from the State University of New York at Buffalo and MBA from the University of Massachusetts at Amherst.
“We greatly welcome Dr. John (Xianfang) Zeng to Chime Biologics to lead our CDMO business to a new level at a critical and rapidly growing period,” said James Huang, executive Chairman of Chime Biologics, ” Chime Biologics is currently investing in expanding capacity and capability, we believe that the onboarding of Dr. Zeng will strengthen company leadership to deliver the strategic and operational objectives and provide CDMO service for Global Supply to our clients with higher quality, speed, efficiency, and state-of-the-art production capacity. ”
“I am very honored to join Chime Biologics,” said Dr. John (Xianfang) Zeng. “Chime Biologics is committed to providing clients with one-stop integrated solutions from early stage drug development to clinical and commercial production for Global Supply. We have recently completed late stage development including process verification/PPQ for one of our early clients to high quality and efficiency standards. This important milestone marks successful completion of a collaboration for the full CMC development process for our clients’ program. I believe that we have demonstrated our capability and capacity to deliver the commercialization and manufacturing services to enable our clients to efficiently develop and launch high quality products to market to benefit patients.”